Calidi Biotherapeutics (CLDI) Total Non-Current Liabilities (2021 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Total Non-Current Liabilities of $5.0 million for Q4 2025, down 58.77% year-over-year from $12.1 million in Q4 2024, and down 24.84% quarter-over-quarter from $6.6 million in Q3 2025.
Calidi Biotherapeutics (CLDI) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Calidi Biotherapeutics' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $5.0 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 58.77% year-over-year to $5.0 million; the TTM figure through Dec 2025 stood at $5.0 million (down 58.77% YoY), while the FY2025 annual figure was $5.0 million, down 58.77% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $5.0 million, down from $6.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $21.3 million in Q1 2024, with the low at $1.1 million in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $9.7 million (2022), against an average of $10.9 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities slumped 93.32% in 2022, then soared 1545.86% in 2023.
- Calidi Biotherapeutics' Total Non-Current Liabilities stood at $16.0 million in 2021, then plunged by 93.32% to $1.1 million in 2022, then jumped by 1545.86% to $17.6 million in 2023, then plunged by 31.45% to $12.1 million in 2024, then slumped by 58.77% to $5.0 million in 2025.
- Business Quant data shows CLDI's Total Non-Current Liabilities at $5.0 million in Q4 2025, $6.6 million in Q3 2025, and $7.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 9.32 Bn |
| 10 | Calidi Biotherapeutics | 1.98 Mn | -2.12 Mn | - | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 Mn |
| Dec 31, 2025 | 4.98 Mn |
| Sep 30, 2025 | 6.63 Mn |
| Jun 30, 2025 | 7.17 Mn |
| Mar 31, 2025 | 7.68 Mn |
| Dec 31, 2024 | 12.09 Mn |
| Sep 30, 2024 | 16.28 Mn |
| Jun 30, 2024 | 18.13 Mn |
| Mar 31, 2024 | 21.33 Mn |
| Dec 31, 2023 | 17.63 Mn |
| Sep 30, 2023 | 16.73 Mn |
| Jun 30, 2023 | 4.58 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 9.03 Mn |
| Jun 30, 2022 | 9.71 Mn |
| Mar 31, 2022 | 14.07 Mn |
| Dec 31, 2021 | 16.04 Mn |